These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37258362)

  • 1. Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
    Lantz J; Portell CA; Ayers EC
    Blood Rev; 2023 Sep; 61():101101. PubMed ID: 37258362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
    Miyazaki K
    Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
    Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
    Thieblemont C; Altmann B; Frontzek F; Renaud L; Chartier L; Ketterer N; Récher C; Poeschel V; Fitoussi O; Held G; Casasnovas O; Haioun C; Morschhauser F; Glass B; Mounier N; Tilly H; Rosenwald A; Ott G; Lenz G; Molina T; Ziepert M; Schmitz N
    Blood Adv; 2023 Aug; 7(15):3968-3977. PubMed ID: 36716220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
    Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
    Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Wilson MR; Eyre TA; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Martinez-Calle N; Preston G; Ahearne M; Schorb E; Moles-Moreau MP; Ku M; Rusconi C; Khwaja J; Narkhede M; Lewis KL; Calimeri T; Durot E; Renaud L; Øvlisen AK; McIlroy G; Ebsworth TJ; Elliot J; Santarsieri A; Ricard L; Shah N; Liu Q; Zayac AS; Vassallo F; Lebras L; Roulin L; Lombion N; Manos K; Fernandez R; Hamad N; Lopez-Garcia A; O'Mahony D; Gounder P; Forgeard N; Lees C; Agbetiafa K; Strüßmann T; Htut TW; Clavert A; Scott H; Guidetti A; Barlow BR; Tchernonog E; Smith J; Miall F; Fox CP; Cheah CY; El Galaly TC; Ferreri AJM; Cwynarski K; McKay P
    Blood; 2022 Apr; 139(16):2499-2511. PubMed ID: 34995350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
    Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
    Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
    Wilson MR; Eyre TA; Martinez-Calle N; Ahearne M; Parsons KE; Preston G; Khwaja J; Schofield J; Elliot J; Mula Kh A; Shah N; Cheung CK; Timmins MA; Creasey T; Linton K; Smith J; Fox CP; Miall F; Cwynarski K; McKay P
    Blood Adv; 2020 Aug; 4(15):3586-3593. PubMed ID: 32761231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
    Wilson MR; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Lees C; Fox C; Preston G; Ahearne M; Strüßmann T; Clavert A; Rusconi C; Ku M; Khwaja J; Narkhede M; Lewis K; Durot E; Smith J; Renaud L; Ferreri AJM; El-Galaly T; Cwynarski K; McKay P; Eyre TA
    Am J Hematol; 2024 Feb; 99(2):E46-E50. PubMed ID: 38037530
    [No Abstract]   [Full Text] [Related]  

  • 17. Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.
    Ho G; Tan C; de Mel S; Poon L; Chan EHL; Lee J; Liu X; Chng WJ; Chee YL; Soon YY; Jeyasekharan AD
    Crit Rev Oncol Hematol; 2021 Nov; 167():103507. PubMed ID: 34656744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
    Tolley ER; Lewinter C; Pedersen LM; Nielsen TH
    Haematologica; 2024 Oct; 109(10):3327-3337. PubMed ID: 38497149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
    Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
    Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
    Malecek MK; Petrich AM; Rozell S; Chu B; Trifilio S; Galanina N; Maurer M; Farooq U; Link BK; Nowakowski GS; Nabhan C; Ayed AO
    Am J Hematol; 2017 Nov; 92(11):1156-1162. PubMed ID: 28719025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.